Rivastigmine

Also known as: Rivastigmine base, 3-[(1S)-1-(Dimethylamino)ethyl]phenyl ethyl(methyl)carbamate, Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, MFCD03700731, S-Rivastigmine, (S)-N-Ethyl-N-methyl-3-[1-(dimethylamino)ethyl]phenyl carbamate

Rivastigmine (CAS 123441-03-2) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C14H22N2O2 and a molecular weight of 250.34 g/mol. Key properties include a boiling point of 316.2±34.0 °C at 760 mmHg, a density of 1.0±0.1 g/cm3 and a flash point of 145.0±25.7 °C. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 123441-03-2
Jingsj CID: J-1978093-9
Molecular Formula: C₁₄H₂₂N₂O₂
Molecular Weight: 250.34 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Boiling Point	316.2±34.0 °C at 760 mmHg
Density	1.0±0.1 g/cm3
Flash Point	145.0±25.7 °C
PSA	147.84000
LogP	2.14
Vapor Pressure	0.0±0.7 mmHg at 25°C
Refractive Index	1.518

Activity & Biological Data

Additional Information	[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805. [2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47. [3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4. [4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

Additional Information

[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805. [2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47. [3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4. [4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

Frequently Asked Questions

What is the CAS number of Rivastigmine?

The CAS number of Rivastigmine is 123441-03-2.

What are the molecular formula and molecular weight of Rivastigmine?

Rivastigmine has molecular formula C14H22N2O2 and molecular weight 250.34 g/mol.

What are the upstream and downstream products of Rivastigmine?

For Rivastigmine, Upstream Products: Ethyl(methyl)carbamic chloride, 3-[(1S)-1-(Dimethylamino)ethyl]phenol, Dimethylamine; Downstream Products: N-Methylethanamine, Carbon dioxide, 3-[(1S)-1-(Dimethylamino)ethyl]phenol.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Rivastigmine (CAS 123441-03-2)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1978093-9 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.